Dongmei M. Yan
Xuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications
Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 06, 2026
Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.
Journal: Blood
Published: February 03, 2026
Identification of multi-drug resistant Acinetobacter baumannii phage YZ2 and evaluation of its therapeutic efficacy in vivo and in vitro.
Journal: Frontiers in microbiology
Published: July 01, 2025
Analysis of Clinical Characteristics and Antimicrobial Resistance in 249 Isolates of Streptococcus mitis: a Single-Centre Study.
Journal: Polish journal of microbiology
Published: May 11, 2025
Within-host novel envZ mutation in Salmonella Enteritidis: Implications for virulence and antibiotic resistance.
Journal: Microbial pathogenesis
Published: March 21, 2025
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.
Journal: The Lancet. Haematology
Published: November 30, 2024
Metformin suppresses gammadelta T17 cell differentiation alleviating DSS-induced colitis.
Journal: Immunologic research
Published: November 10, 2024
Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial.
Journal: Leukemia research
Published: August 14, 2024
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.
Journal: Blood advances
Published: July 10, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.
Journal: The Lancet. Haematology
Published: March 10, 2024
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.
Journal: Annals of hematology
Published: January 29, 2024
Allogeneic hematopoietic stem cell transplantation combined with CD7 CAR-T for the treatment of T lymphoblastic lymphoma: a case report and literature review
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: December 04, 2023
Last Updated: 09/26/2026